Abstract B243: A phase I dose-escalation study of MEK inhibitor MEK162
- This topic has 0 replies, 1 voice, and was last updated 12 years, 6 months ago by
.
Viewing 1 post (of 1 total)
-
Posts
-
Abstract B243: A phase I dose-escalation study of MEK inhibitor MEK162 (ARRY-438162) in patients with advanced solid tumors.
http://mct.aacrjournals.org/cgi/content/short/10/11_MeetingAbstracts/B243?rss=1
Viewing 1 post (of 1 total)
- The forum ‘New Developments’ is closed to new topics and replies.